NA
BNTX icon

Navellier & Associates’s BioNTech BNTX Stock Holding History

Navellier & Associates’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,652
Closed -$5.84M – 291
2021
Q4 		$5.84M Buy
22,652
+430
+2% +$118K 0.85% 31
2021
Q3 		$6.07M Sell
22,222
-825
-4% -$262K 0.91% 34
2021
Q2 		$5.16M Buy
+23,047
New +$4.35M 0.78% 38

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Navellier & Associates's BNTX Position: Q1 2022 in Review

Navellier & Associates sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 22,652 shares — an estimated $5.84M sold.

Navellier & Associates first reported a position in BNTX in Q2 2021 and held it in 3 quarters. The position peaked at $6.07M in Q3 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

  • Navellier & Associates reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
  • Navellier & Associates sold 22,652 BioNTech shares in Q1 2022, an estimated $5.84M.
  • Navellier & Associates first reported a position in BioNTech in Q2 2021 and held it in 3 quarters.
  • Navellier & Associates's BioNTech position peaked at $6.07M in Q3 2021.
  • 287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on Navellier & Associates's 13F filing for Q1 2022, filed 29 Apr 2022.